Initial Treatment for Connective Tissue Disorders

First-Line Treatment Options

The American College of Rheumatology recommends methotrexate as first-line therapy for connective tissue disorders, unless contraindicated, with consideration for short-term low-dose glucocorticoids as bridging therapy until methotrexate takes effect 1
Short-term low-dose glucocorticoids (≤10 mg/day prednisone equivalent) can be used as bridging therapy until methotrexate becomes effective (typically 6-12 weeks), as suggested by the Mayo Clinic 1, 2
For patients with contraindications to methotrexate, alternative first-line options include leflunomide or sulfasalazine, according to Praxis Medical Insights 1

The American College of Rheumatology recommends starting methotrexate at 15-25 mg/week (as tolerated) for patients with rheumatoid arthritis, with a moderate level of evidence 3
For patients with high disease activity at 3 months despite optimized MTX and prednisone, the Mayo Clinic suggests considering adding biologic therapy such as TNF inhibitors or abatacept, with a moderate level of evidence 3
Triple therapy (methotrexate + sulfasalazine + hydroxychloroquine) is an effective alternative to biologic therapy for patients with inadequate response to MTX monotherapy, as recommended by Praxis Medical Insights 1

The American Thoracic Society recommends mycophenolate as the preferred first-line therapy for interstitial lung disease associated with most connective tissue disorders, with a strong level of evidence 4
Other first-line options include azathioprine and rituximab, according to Arthritis and Rheumatology 4
There is a strong recommendation against long-term glucocorticoids for interstitial lung disease in systemic sclerosis due to risk of scleroderma renal crisis, as suggested by Arthritis and Rheumatology 4

Disease activity should be monitored frequently (every 1-3 months) during active disease, as recommended by Praxis Medical Insights 1
If no improvement is seen by 3 months or the target is not reached by 6 months, therapy should be adjusted, according to Praxis Medical Insights 1
For patients with persistent moderate to high disease activity despite initial therapy, treatment escalation should be considered within 6 months, as suggested by the Mayo Clinic 3

Patients with connective tissue disorders who require DMARDs or biologics should be referred to a chest physician for assessment before treatment if there is concern for lung involvement, as recommended by Thorax 5
Patients with co-morbid rheumatoid arthritis and bronchiectasis may have worse outcomes than those with either disease alone, according to Thorax 5
Immunosuppressive treatments are associated with higher risk of infection; biologics may promote infections more than traditional DMARDs, as suggested by Thorax 5
Patients must be in persistent low disease activity or remission for at least 6 months before considering any tapering of DMARDs, as recommended by Praxis Medical Insights 6